CoChat

Recent Advances in HIV-1 Gag Inhibitor Design and Development

Open access
Dick, Alexej, Cocklin, Simon · 2020 · Molecules

The DOI matches its Crossref record; 150 of the 153 references it cites were found in a registry or an index.

Abstract

Acquired Immune Deficiency Syndrome (AIDS) treatment with combination antiretroviral therapy (cART) has improved the life quality of many patients since its implementation. However, resistance mutations and the accumulation of severe side effects associated with cART remain enormous challenges that need to be addressed with the continual design and redesign of anti-HIV drugs. In this review, we focus on the importance of the HIV-1 Gag polyprotein as the master coordinator of HIV-1 assembly and maturation and as an emerging drug target. Due to its multiple roles in the HIV-1 life cycle, the individual Gag domains are attractive but also challenging targets for inhibitor design. However, recent encouraging developments in targeting the Gag domains such as the capsid protein with highly potent and potentially long-acting inhibitors, as well as the exploration and successful targeting of challenging HIV-1 proteins such as the matrix protein, have demonstrated the therapeutic viability of this important protein. Such Gag-directed inhibitors have great potential for combating the AIDS pandemic and to be useful tools to dissect HIV-1 biology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules25071687

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Domain architecture of the Gag precursor polyprotein. The function (bottom) and type of interaction (top) are highlighted. Matrix (MA) is responsible for Gag targeting to cholesterol-enriched lipid rafts for virus budding at the plasma membrane (PM) and incorporation of Env. Capsid (CA) is crucial for Gag assembly and the formation of the conical core structure. Interaction with host cell factors such as cyclophilin A (CypA) or transportins regulates the nuclear import of the pre-integration complex. SP1 is involved in Gag assembly. Nucleocapsid (NC) is involved in Gag assembly and, with its two zinc fingers, binds to RNA and exerts RNA chaperone activity. P6 is involved in the recruitment of the endosomal sorting complex required for transport (ESCRT) for virus egress and in Vpr incorporation.
Figure 1 Domain architecture of the Gag precursor polyprotein. The function (bottom) and type of interaction (top) are highlighted. Matrix (MA) is responsible for Gag targeting to cholesterol-enriched lipid rafts for virus budding at the plasma membrane (PM) and incorporation of Env. Capsid (CA) is crucial for Gag assembly and the formation of the conical core structure. Interaction with host cell factors such as cyclophilin A (CypA) or transportins regulates the nuclear import of the pre-integration complex. SP1 is involved in Gag assembly. Nucleocapsid (NC) is involved in Gag assembly and, with its two zinc fingers, binds to RNA and exerts RNA chaperone activity. P6 is involved in the recruitment of the endosomal sorting complex required for transport (ESCRT) for virus egress and in Vpr incorporation.CC BY · PubMed Central
Figure 2 Surface conservation of the HIV-1 Gag polyprotein and inhibitor target sites. Alignment of 9547 HIV-1 Gag sequences were retrieved from the HIV Los Alamos database (www.hiv.lanl.gov). Sequences were aligned against the HxBc2 reference. Conservation analysis was performed using the ConSurf server [10]. Structures of the HIV-1 Gag domains with PDB entries: matrix, 2H3Z; capsid, 6ES8; sp2, 1U57; nucleocapsid, 2M3Z; p6, 2C55. Orange boxes represent target sites for inhibitor binding highlighted in this review. Low conservation in light cyan to high conservation in dark purple.Gag’s constituent proteins act at different points in the viral life cycle. MA binds specifically to phosphoinositide 4,5-bisphosphate (PI [4,5]P2) and specific phospholipids on the plasma membrane, triggering the exposure of an attached myristoyl (myr) chain and directing Gag to the membrane. This membrane interaction is required for the correct incorporation of the viral envelope protein (Env) into the budding virus [11,12,13,14]. In the late stages of the replication cycle, CA is responsible for the assembly of Gag at the plasma membrane by providing intermolecular contact sites for Gag oligomerization at the plasma membrane [15,16]. In the early stages of replication, CA disassembly regulates the process of reverse transcription, and its engagement of cellular transportins and nuclear pore components facilitate the import of the viral pre-integration complex into the nucleus, where integration takes place [17]. NC functions as a nucleic acid chaperone at multiple steps in the HIV-1 replication cycle, and it’s overall positively charged character and two zinc-finger motifs allow it to interact with viral genomic RNA via the RNA packaging signal and thereby facilitate virion assembly [18,19,20,21]. Finally, the p6 domain (late domain) recruits the endosomal sorting complex required for transport (ESCRT) machinery to promote virus budding and final release [22]. Two spacer peptides (SP1 and SP2) flanking the NC domain regulate the kinetics of Gag maturation, and SP1 also provides, as part of the C-terminus of CA, another Gag-Gag multimerization interface [23,24]. Because Gag functions in so many different aspects of viral infection and replication, Gag inhibitors have the potential to exert their effects in both early and late stages of the replication cycle, making this polyprotein a particularly attractive target for the development of new therapeutics.
Figure 2 Surface conservation of the HIV-1 Gag polyprotein and inhibitor target sites. Alignment of 9547 HIV-1 Gag sequences were retrieved from the HIV Los Alamos database (www.hiv.lanl.gov). Sequences were aligned against the HxBc2 reference. Conservation analysis was performed using the ConSurf server [10]. Structures of the HIV-1 Gag domains with PDB entries: matrix, 2H3Z; capsid, 6ES8; sp2, 1U57; nucleocapsid, 2M3Z; p6, 2C55. Orange boxes represent target sites for inhibitor binding highlighted in this review. Low conservation in light cyan to high conservation in dark purple.Gag’s constituent proteins act at different points in the viral life cycle. MA binds specifically to phosphoinositide 4,5-bisphosphate (PI [4,5]P2) and specific phospholipids on the plasma membrane, triggering the exposure of an attached myristoyl (myr) chain and directing Gag to the membrane. This membrane interaction is required for the correct incorporation of the viral envelope protein (Env) into the budding virus [11,12,13,14]. In the late stages of the replication cycle, CA is responsible for the assembly of Gag at the plasma membrane by providing intermolecular contact sites for Gag oligomerization at the plasma membrane [15,16]. In the early stages of replication, CA disassembly regulates the process of reverse transcription, and its engagement of cellular transportins and nuclear pore components facilitate the import of the viral pre-integration complex into the nucleus, where integration takes place [17]. NC functions as a nucleic acid chaperone at multiple steps in the HIV-1 replication cycle, and it’s overall positively charged character and two zinc-finger motifs allow it to interact with viral genomic RNA via the RNA packaging signal and thereby facilitate virion assembly [18,19,20,21]. Finally, the p6 domain (late domain) recruits the endosomal sorting complex required for transport (ESCRT) machinery to promote virus budding and final release [22]. Two spacer peptides (SP1 and SP2) flanking the NC domain regulate the kinetics of Gag maturation, and SP1 also provides, as part of the C-terminus of CA, another Gag-Gag multimerization interface [23,24]. Because Gag functions in so many different aspects of viral infection and replication, Gag inhibitors have the potential to exert their effects in both early and late stages of the replication cycle, making this polyprotein a particularly attractive target for the development of new therapeutics.CC BY · PubMed Central
Figure 3 Structure of maturation inhibitors (MI) discussed in this review. (1) Bevirimat (BVM); (2) PF-46396; (3) GSK3532795.
Figure 3 Structure of maturation inhibitors (MI) discussed in this review. (1) Bevirimat (BVM); (2) PF-46396; (3) GSK3532795.CC BY · PubMed Central
Figure 4 MA inhibitors targeting the PI[4,5]P2 binding site. (A) The NMR structure of MA with its myristic acid (in yellow) buried in a hydrophobic groove at the N-terminus (PDB code: 2H3I). (B) The NMR structure of MA bound to di-C4-PI[4,5]P2 displacing the myristic acid (PDB code: 2H3Z). (C) Docking model of compound 7 bound to MA and displacing di-C4-PI[4,5]P2. In red are the residues highlighted that are involved in di-C4-PI[4,5]P2 binding.
Figure 4 MA inhibitors targeting the PI[4,5]P2 binding site. (A) The NMR structure of MA with its myristic acid (in yellow) buried in a hydrophobic groove at the N-terminus (PDB code: 2H3I). (B) The NMR structure of MA bound to di-C4-PI[4,5]P2 displacing the myristic acid (PDB code: 2H3Z). (C) Docking model of compound 7 bound to MA and displacing di-C4-PI[4,5]P2. In red are the residues highlighted that are involved in di-C4-PI[4,5]P2 binding.CC BY · PubMed Central
Figure 5 Structure of MA inhibitors discussed in this review. (4) TD2; (5) compound 7; (6) compound 14.
Figure 5 Structure of MA inhibitors discussed in this review. (4) TD2; (5) compound 7; (6) compound 14.CC BY · PubMed Central
Figure 6 HIV-1 MA trimerization is essential for HIV-1 Env incorporation. Residues involved in the trimerization interface Gln62 in orange and Ser66 in yellow are putative target sites for novel inhibitor designs. PDB code: 1HIW.
Figure 6 HIV-1 MA trimerization is essential for HIV-1 Env incorporation. Residues involved in the trimerization interface Gln62 in orange and Ser66 in yellow are putative target sites for novel inhibitor designs. PDB code: 1HIW.CC BY · PubMed Central
Figure 7 CA Inhibitors and binding site locations. CA is depicted in the context of a hexamer (left), and inhibitor/peptide-binding site is highlighted in the monomer (right). PDB code: 6ES8.
Figure 7 CA Inhibitors and binding site locations. CA is depicted in the context of a hexamer (left), and inhibitor/peptide-binding site is highlighted in the monomer (right). PDB code: 6ES8.CC BY · PubMed Central
Figure 8 Structure of CA inhibitors discussed in this review. (7) CAP-1; (8) CAI; (9) NYAD-1; (10) NYAD-13; (11) BD-1; (12) BM-1; (13) PF74.
Figure 8 Structure of CA inhibitors discussed in this review. (7) CAP-1; (8) CAI; (9) NYAD-1; (10) NYAD-13; (11) BD-1; (12) BM-1; (13) PF74.CC BY · PubMed Central
Figure 9 Structure of CA inhibitors discussed in this review. (14) BD-1; (15) BM-1; (16) C1; (17) GS-CA1; (18) GS-6207.
Figure 9 Structure of CA inhibitors discussed in this review. (14) BD-1; (15) BM-1; (16) C1; (17) GS-CA1; (18) GS-6207.CC BY · PubMed Central
Figure 10 NMR complex structure with an NCI (compound 3) (2:1 stoichiometry). The NCI binds within a hydrophobic pocket and is stabilized by π-π stacking with Trp37 (highlighted in green). The model was derived from PDB code: 2M3Z. Zn2+ ions are represented as orange balls in both zinc fingers.
Figure 10 NMR complex structure with an NCI (compound 3) (2:1 stoichiometry). The NCI binds within a hydrophobic pocket and is stabilized by π-π stacking with Trp37 (highlighted in green). The model was derived from PDB code: 2M3Z. Zn2+ ions are represented as orange balls in both zinc fingers.CC BY · PubMed Central
Figure 11 Structure of NC inhibitors discussed in this review. (19) NOBA; (20) DIBA; (21) PATE; (22) SAMT; (23) trans-chlorobispyridine (9-ethylguanine)platinum(II); (24) NVO38; (25) WDO-217.
Figure 11 Structure of NC inhibitors discussed in this review. (19) NOBA; (20) DIBA; (21) PATE; (22) SAMT; (23) trans-chlorobispyridine (9-ethylguanine)platinum(II); (24) NVO38; (25) WDO-217.CC BY · PubMed Central
Figure 12 Zinc ejecting mechanisms: Class 1) Electrophilic attack of the zinc fingers. The nucleophilic attack of the cysteine 39 results in the formation of a thioester by SAMTs. This covalent linkage stimulates the reaction of additional reactants with the other Cys residues of the same motif and leads to reduction in Zn2+ affinity of the zinc finger and finally zinc ejection and NC unfolding [131]. Class 2) Zinc chelation by the two carbonyl oxygens of the ester from NVO38 [133]. Class 3) Covalent binding of Cys residues by platinum (Pt) as represented by trans-chlorobispyridine(9-ethylguanine)platinum(II) [137]. Cys (N) and Cys (C) represent N-terminal and C-terminal cysteines in the zinc finger.
Figure 12 Zinc ejecting mechanisms: Class 1) Electrophilic attack of the zinc fingers. The nucleophilic attack of the cysteine 39 results in the formation of a thioester by SAMTs. This covalent linkage stimulates the reaction of additional reactants with the other Cys residues of the same motif and leads to reduction in Zn2+ affinity of the zinc finger and finally zinc ejection and NC unfolding [131]. Class 2) Zinc chelation by the two carbonyl oxygens of the ester from NVO38 [133]. Class 3) Covalent binding of Cys residues by platinum (Pt) as represented by trans-chlorobispyridine(9-ethylguanine)platinum(II) [137]. Cys (N) and Cys (C) represent N-terminal and C-terminal cysteines in the zinc finger.CC BY · PubMed Central
Figure 13 Solution NMR structure of Tsg101 complexed with N16. N16 binds in a hydrophobic groove defined by Thr56 (in green), similar to other peptide-based Tsg101 inhibitors. (26) N16. PDB code: 5VKG.
Figure 13 Solution NMR structure of Tsg101 complexed with N16. N16 binds in a hydrophobic groove defined by Thr56 (in green), similar to other peptide-based Tsg101 inhibitors. (26) N16. PDB code: 5VKG.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 150 references

Research works printed but not linked: 2

  1. Tse, W.C., Link, J.O., Mulato, A., Niedziela-Majka, A., Rowe, W., Somoza, J.R., Villasenor, A.G., Yant, S.R., Zhang, J.R., and Zheng, J. (2017, January 13–16). Discovery of Novel Potent HIV Capsid Inhibitors with Long-acting Potential. Proceedings of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA.
  2. Yant, S.R., Mulato, A., Stepan, G., Villasenor, A.G., Jin, D., and Margot, N.A. (2019, January 4–7). GS-6207, a potent and selective first-in-class long-acting HIV-1 capsid inhibitor. Proceedings of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA.

Cited by

See all 31

Metadata

Authors
Dick, A., & Cocklin, S.
Affiliations
Drexel University (US)
Corresponding author
Cocklin, Simon
Venue
Molecules
Publisher
MDPI AG
Published
2020-04-07
Volume
25
Issue
7
Pages
1687
ISSN
1420-3049 (ISSN-L)
OpenAlex
W3015551811
Cited by
28
References
153
Citations by year
2026: 3 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 8 · 2020: 1
FWCI
0.25
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (NS089435, GM125396)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
HIV-1 Gag polyprotein, capsid protein, matrix protein, antiretroviral drug design, drug resistance, HIV-1 life cycle
MeSH terms
Acquired Immunodeficiency Syndrome, Humans, HIV-1, HIV Protease Inhibitors, Anti-HIV Agents, Drug Resistance, Viral, Capsid Proteins, gag Gene Products, Human Immunodeficiency Virus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recent Advances in HIV-1 Gag Inhibitor Design and Development. https://app.cochat.ai/papers/10.3390/molecules25071687
The paper
Dick, A., & Cocklin, S. (2020). Recent Advances in HIV-1 Gag Inhibitor Design and Development. Molecules. https://doi.org/10.3390/molecules25071687

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.